No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate‐to‐severe plaque psoriasis. (1st February 2018) - Strober, B.E.; Langley, R.G.B.; Menter, A.; Magid, M.; Porter, B.; Fox, T.; Safi, J.; Papavassilis, C.